Ibrahim Halil SAHIN, MD
@IbrahimSahinMD1
Followers
3K
Following
4K
Media
247
Statuses
3K
Medical Oncologist| NCI Colon Task Force|Clinical trialist-Mentor| Research: Precision Medicine-Immunotherapy-Colorectal CA-EOCRC | Patient Advocacy | Musician
Joined December 2018
✳️Colorectal cancer is now the leading cause of cancer related death among males aged 20-39 and 40-49 ‼️It was third among 20-39 age group last year. ✳️ Concerning trend is also seen in young women; CRC related death and will likely surpass breast cancer in near future @OncoAlert
30
365
713
An important question I receive from my patients is that sugar fuels the cancer and whether if they need to fast or follow a low carb diet❗️This is in fact very important subject particular for patients with GI cancers @oncoalert @CrcChange @manjuggm @fireflyann . Here is why 👇.
6
46
184
I am seeing several young CRC patients at their early 30s and 40s begging for colonoscopy for rectal bleeding/ abdominal pain over SEVERAL months ! .👉We must increase awareness of Early onset CRC among our PCP and GP colleagues‼️.👉#EoCRC is an epidemic in the US‼️‼️.@OncoAlert.
5
40
133
#PrayForTurkey. My mom and some siblings lives in Gaziantep where the earthquake occurred ! Thankfully they are safe but so many others are still under collapsed buildings! Never felt that helpless …. Please pray for Turkey ❗️
22
9
131
✳️I am thrilled to share that I am appointed to @theNCI Colon Task Force as Alliance Early Career Investigator starting 01/2024❗️. I would like to thank Dr Meyerhardt and Dr @EileenMOReilly for nominating me for this position❗️. @UPMCHillmanCC @PittDeptofMed.
20
15
121
#ASCO22.✳️Happy to say there is great progress for patients with CRC‼️.@OncoAlert @ASCO @manjuggm @CrcChange‼️ .Here is summary of some key studies 👇.
5
40
123
✳️Our article on neoadjuvant IO for MMR-D/MSI-H colon and rectal cancer is now out ‼️ @JCOOP_ASCO @OncoAlert @ASCO .✳️Happy this came out in #colorectalcancerawareness month ❗️.👇Here some key points from this article ❗️.
6
42
119
My patient with MMR-D rectal cancer now into 3 months of pembrolizumab and achieved complete radiological response by MRI ‼️. ✳️This was one of the most amazing news to share lately with so much joy and emotion ‼️. ✳️IOs do work very well in MMR-D rectal cancer ‼️. @OncoAlert.
3
16
110
✳️Our article on the value of ctDNA for management of patients with rectal cancer management is out ‼️. Thrilled to work with Dr @adasarimd on this one ‼️. ✳️Some key points 👇. @manjuggm @CrcTrialsChat @colontown
6
29
109
✳️The paper that we discussed the role of neoadjuvant IO therapy for pts with MSI-H colon and rectal cancer is now accepted for publication ❗️.✳️We reviewed the recent ground breaking progress and elaborated on challenges and future opportunities ❗️@OncoAlert @JCOOP_ASCO @ASCO
7
15
107
I would like to do my 2nd deep dive post #ASCO22 analysis on #ctDNA guided adjuvant therapy for pts with stage II colon cancer‼️. ✳️The DYNAMIC trial is certainly step forward (kudos) ‼️But doesn’t answer many questions❗️@OncoAlert @manjuggm @CrcChange @TheColonClub Why ?👇
3
32
108
✳️ I am thrilled to share that I received David Roodman Mentoring Award last week ❗️It is a true honor❗️. ✳️The most rewarding award for me, on the hand, is the growth and successes of my mentees ‼️ It is a true privilege and joy to join their journey and help their growth and
15
7
103
✳️It takes a village to make an idea to come to life as an investigator initiated trial but so glad this study will be activated soon with a hope bring new breath to the management of patients with MSI-H CRC‼️. #GI24 . @doctorC369 @ronanhsieh @Dr_M_Tejani @AnwaarSaeed3 @ASCO
3
10
96
#ASCO22.✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward ! . ✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️. However there are important points that we need to address 👇@asco @OncoAlert @MoffittNews
2
31
95
✳️Thrilled to contribute to this work now published by @CancerNetwrk Oncology Journal❗️. ✳️Was amazing to work with Dr.@adasarimd and Dr Lieu and all co-authors ❗️. ✳️Here are some key points from CIRCULATE US trial discussed here 👇 @OncoAlert @manjuggm
5
29
93
Thrilled to announce that I will be joining to @UPMCnews - @UPMCHillmanCC❗️Look forward to excel my research on CRC/EoCRC, contribute its changing treatment paradigm‼️. Also, so excited that our paths are crossing with Dr @teekayowo once again❗️. My mentors @EileenMOReilly, +.
15
8
91
✳️A nice article showing tumor mutation burden alone relatively irrelevant for IO response among MSS GI cancers particularly for MSS CRC❗️. Why?👇. @OncoAlert @TheColonClub @TheColonClub @manjuggm @UPMCHillmanCC .
2
37
93
#ASCO22. ✳️Our article for ASCO Educational Book is now accepted for publication ❗️.✳️We have discussed challenges and opportunities of immunotherapy for patient with MSS CRC❗️.✳️Stay tuned for this highly exciting paper ‼️.@ASCO #ASCOEdBook.@OncoAlert.
2
10
86
An important question I hear from my patients is what vitamins to take while being on chemotherapy‼️. ✳️Perhaps, the question should also be asked as “which vitamins to not to take” while being chemotherapy @oncoalert @CrcChange @fireflyann @manjuggm . Here is why👇.
5
24
89
✳️Although could not make it to ESMO, here are some my personal comments regarding some of key studies in CRC space ❗️. @OncoAlert @CrcTrialsChat @manjuggm @TheColonClub @colontown . 👉 Let’s start with G12C targeting in CRC space ‼️
1
26
94
✳️Starting to ASCO GI with a great news ❗️.✳️ Our paper on the role of Immunotherapy for patients living with MSS CRC is now accepted for publication ‼️. Stay tuned for this exciting article overviewing the literature and unmet needs ‼️. @DenizCanGuven1 @AnwaarSaeed3 @manjuggm
8
10
90
1️⃣. ✳️I would like to dedicate my first tweetorial for Early onset CRC, as I truly believe it is an Epidemic that we know little about it❗️.✳️CRC is now the leading cause of cancer related death among males among aged 20-49 ❗️ @CrcChange @oncoalert.#ColorectalCancerAwarenessMonth
3
39
86
I was honored to join #ClinicalTrialsForum at @WhiteHouse @WHOSTP ‼️. ✳️So encouraged that there is huge awareness that we need to improve the whole clinical trial operating system starting from making them more pragmatic and friendly for patients to deliver them as decentralized
5
6
80
#ColorectalCancerAwarenessMonth.1️⃣.✳️Dedicating my third tweetorial for precision oncology for pts with metastatic CRC❗️. ✳️We have now several actionable genes with novel agents for pts with CRC! Highlights 👇❗️ @manjuggm @colontown @crcchange @thecolonclub @upmchillmancc.
6
29
76
#GI22 @ASCO @OncoAlert .✳️CtDNA📈 establishes itself as the single most important prognostic factor in CRC after sx ❗️.✳️Patients with negative CtDNA seems to be doing well without ACT however we need randomized trials to establish this #CIRCULATE-US #COBRA.@CrcChange @FightCRC
1
20
72
✳️KRAS oncogene, famed as undruggable target, is now potentially actionable particularly G12C mutant !.✳️How did this perception change? I will go over some recent progress in this tweetorial for KRAS mutant CRC ❗️.@OncoAlert @manjuggm @UPMCHillmanCC.👇.
5
21
76
Our paper on HER2 targeting for patients with CRC is out‼️ @ASCO @JCOOP_ASCO . ✳️In this article we have discussed recent updates and future opportunities @oncoalert . Here are some important points discussed👇.
8
23
74
#ColorectalCancerAwarenessMonth.✳️ Management of patients of early stage colon cancer have been evolving into precision approach step by step ! In this tweetorial, will overview adjuvant therapy approaches for patients with colon cancer❗️@OncoAlert @manjuggm @CrcChange.
4
28
73
#esmo22. ✳️ Some take home CRC updates in @myESMO highly promising yet needing some discussion‼️. @OncoAlert @CrcChange @manjuggm @fireflyann . Here are some my humble thoughts 👇.
3
23
73
👉BRAF mutations are now actionable in CRC. 👉However, it is critical to define distinct molecular subgroups of BRAF mutants. 👉In this work, we developed an algorithmic precision approach for the management of mCRC with a BRAF alterations.@ASCO @ASCO_pubs @OncoAlert
4
27
70
✳️Our work regarding the role of immunotherapy for neoadjuvant treatment of MSI-H Gastrointestinal Cancer is now out ‼️. @OncoAlert @UPMCHillmanCC @AnwaarSaeed3 @CrcTrialsChat @manjuggm . Here are some key messages 👇.
1
21
72
✳️It is not surprising anymore to see Dr @MyriamChalabi presenting some mind blowing data and no questions these are impactful to practice ‼️. ✳️I think it is still important to entertain some thought process and some discussion around these impressive results 👇. @manjuggm
1
14
71
✳️Our article discussing the role of immunotherapy for patients with MSS CRC with TMB high is now out ‼️. Here are some key messages 👇. @UPMCHillmanCC @OncoAlert @CrcTrialsChat @manjuggm @CharanVegivinti @AnwaarSaeed3
3
24
70
ASCO #GI23 CRC highlights -2. ✳️Sunlight trial phase III RCT is positive, confirming superiority of Lonsurf Avastin compared to Lonsurf monotherapy with improved OS and PFS❗️Bevacizumab should be added to lonsurf if used (when no actionable gene) period ❗️.@OncoAlert
1
17
67
ASCO #GI23 CRC highlights . ✳️Really excited to see new generation of immune checkpoint inhibitors showing good activity in CRC ❗️#Botensilimab #balstilimab.✳️While we need to more data, I am hopeful we will break immune cold nature of MSS CRC in near future ❗️@OncoAlert
1
16
67
✳️Our Editorial on the PROSPECT trial is now officially out ‼️ . ✳️We elaborated on implications of the PROSPECT and also discussed limitations of this landmark study‼️ . ✳️We were truly thrilled to work with @ARosen380 and @manjuggm to make sure patients voice is included this
5
17
69
Some interesting findings of Galaxy trials from my view :.✳️Cumulative clearance rate was high but then even 19% of those who cleared #ctDNA, had disease recurrence in 18 months ‼️.✳️This means ctDNA clearance does not always mean a cure, rather just undetectable ❗️@OncoAlert
4
22
65
✳️While concluding the #ColorectalCancerAwarenessMonth just received this amazing news !!. ✳️Our paper on KRAS targeting for patients with CRC is now accepted for a publication in @JCOOP_ASCO ‼️.✳️We discussed the recent progress and elaborated future therapeutic opportunities
8
7
65
✳️NAPOLI-3 trial is positive and improves both OS and PFS compared to gemcitabine abraxane ❗️.✳️However OS is similar to FOLFIRINOX (11.1 vs 11.1). ❗️.✳️High rates of diarrhea is not surprising in investigational arm❗️.@OncoAlert
1
15
64
✳️I was thrilled to join @WhiteHouse Cancer Moonshot Colorectal Cancer Listening Session ❗️.✳️I am more hopeful than ever that clinical trials and trial opening process can be revolutionized to improve inclusivity and accessibility particularly for patients with young onset
8
9
59
✳️Our article on KRAS targeting approaches for patients with CRC is now out ‼️. ✳️In this exciting article we summarized the recent progress which resulted in practice changing outcomes and elaborated on future opportunities ‼️. Here are some key points 👇. @JCOOP_ASCO @ASCO
4
14
62
Some goodbyes are really hard in oncology… . Some last talks that I wish I never had to do, are really challenging …. Joining to the journey of my patients has been a true privilege ‼️ Yet, the last hug, the last words, and the last goodbye can be overwhelming….
2
5
62
✳️Although my research is purely focused colorectal cancer, I was delighted to work on this pancreatic cancer project with Dr @SalemGIOncDoc @elrefai_sara ‼️ .✳️Also being mentee of an international PDAC expert @EileenMOReilly was helpful to put this together ☺️.✳️Some important
.@IbrahimSahinMD1, @elrefai_sara & @SalemGIOncDoc discuss the importance of germline #GeneticTesting in all pts w/ PDAC, regardless of stage of disease & family history at the time of diagnosis: #gicsm #ASCODailyNews
4
14
61
Was great to be back to my medical school #Hacettepe University to meet with young and brilliant minds in person and chat about cancer science and academia❗️ . ✳️Exciting to see the future of science is bright with many young and dedicated physicians/scientists ‼️
0
3
57
HER2 targeting for patients with CRC continues to evolve ‼️. ✳️With recent data on the Mountaineer trial it is time to overview #HER2 targeting for pts with CRC @oncoalert @manjuggm @fireflyann @CrcChange . Some important points to consider👇.
2
21
60
✳️Our paper discussing the role of ctDNA for the management of patients with early stage colon is now out ‼️. ✳️CtDNA is rapidly evolving and it is here to stay ❗️In this article we discussed the pros and cons of ctDNA and it is relevance to personalized adjuvant therapy ❗️Here
2
17
63
✳️Alarming numbers for Early Onset Colorectal Cancer seen last year statistics (representing 2020) continues to be noted in this year statistics (representing 2021 data) while incidence in overall population continues to go down (effective screening for those >45)‼️ .✳️CRC, once
3
26
60
✅ It is always so refreshing to meet and catch up with your mentors; particularly if your life long mentor, Dr @EileenMOReilly ☺️ . @ALLIANCE_org
0
4
60
The last day at work ✅. As a son of farmer family from small town Turkey, it was not a straight path and it won’t be❗️. I have chased my dreams/goals;will continue to do so and MLK’s inspiring words will continue to ring in my ears during this journey❗️.
1
5
56
✳️Heading to Turkiye for International Gastrointestinal Cancer meeting ❗️.✳️Excited to reconnect . colleagues from homeland and Europe and share the progress in the field‼️. #IGICC2024
6
0
55
#ColorectalCancerAwarenessMonth.1️⃣.✳️I would like to dedicate my second tweetorial for KRAS targeting❗️. ✳️KRAS oncogene, long considered undruggable, now potentially actionable though there are hurdles we need to overcome for non-G12C👇❗️ @oncoalert @ @colontown @TheColonClub.
4
14
55
✳️Got my ID badge and ready for #ASCO24 ‼️. ✳️Looking forward to reconnecting with colleagues and friends from academia, pharma/industry and patient advocacy ☺️ Excited ‼️. @ASCO @manjuggm @CrcTrialsChat .@colontown @TheColonClub @FightCRC
8
4
54
Our paper is out ‼️.✳️The study that we investigated prognostic markers of MSI-H CRC in a cohort of over 1100 patients is now published in the @OncJournal. @CrcChange @OncoAlert @ElaineTanMD.✳️We identified age and BRAF mutations as prognostic markers ❗️.
4
14
51
#Day1 @UPMCHillmanCC . ✳️So excited to start to this new journey ❗️ . ✳️ Look forward to continue to contribute to the science to advance management of colorectal cancer for our patients ‼️. @teekayowo .@OncoAlert @CrcChange @manjuggm .#Sciencematters ❗️
4
5
53
✳️I was thrilled to give a talk on my clinic trials (NCT06365970, NCT06006923) in which we aim to optimize tumor microenvironment and enhance antitumor immune response #IOsummit @CHI_Healthtech ‼️. ✳️We will be conducting several correlative analysis once studies are completed to
4
3
49
Pancreatic cancer stroma remains a dilemma for physicians scientist! In our study with @EileenMOReilly and Gokce Askan we identified that patients with dense stroma had lower cumulative local recurrence compared to pts with loose stroma! 👉 @OncoAlert
3
15
49
Made it home with this amazing news❗️. ✳️Humbled to be the first author of the very first paper of CIRCULATE-US❗️. We discussed the rationale, study design and key tips of pts enrollment ❗️@oncoalert.@EileenMOReilly . Was amazing to work Dr Dasari and Dr Lie ❗️True Honor❗️
3
8
51
✳️This concerning trend warrants urgent intervention and more science to better understand the biological underpinnings of the #CRC epidemic in the US‼️.@CrcChange @CrcTrialsChat @FightCRC @manjuggm @TheColonClub @TheColonClub.
3
11
47
ASCO #GI23. @UPMCHillmanCC GI Oncology crew on their way to ASCO #GI23 ☺️.@AnwaarSaeed3 @JanieYZhang
2
4
50
✳️More data from Galaxy-Japan is highly encouraging for de-escalation arm (MRD - negative) of CIRCULATE-NA and also indicates significant unmet need for MRD positive arm ❗️.✳️Although this is observational data, the predictive value for ctDNA for appears to be highly promising
3
18
51
The truck is now loaded for the new journey to Pittsburgh ‼️. #academiclife #pursueTheScience #chaseyourdreams
2
2
50
✳️There is no better to start to your weekend than having brunch with your mentees .😊.@paozinser @dogakahramangil . @PittDeptofMed
3
2
50
A @nature paper suggests B-Hyroxybutyrate suppresses CRC and hereby ketogenic diet can be also considered for CRC treatment❗️. ✳️The study is intriguing, yet many important points need discussion before concluding sugar fuels cancer👇@OncoAlert @CrcChange .
1
11
47
A 6-2.📌TNT is not recommended for pts with MSI-H #RectalCancer !!.📌 Pts with MSI-H LARC may have dz progression with induction or consolidation chemo, not common in pts with MSS LARC. 📌NCCN now endorses ICI tx for MSI-H pts with intention for organ preservation.#CRCTrialsChat.
1
16
48
#ASCO22. ✳️The standard of care for MMR-D rectal cancer is changing/changed❗️.✳️We should do all we can to avoid surgery for patients with MMR-D rectal cancer ❗️.✳️Although data is early and it is highly promising enough to move forward ‼️@asco @OncoAlert @MoffittNews .👇
3
16
47
✳️Completed my last clinic, and I have say it has been very emotional last few weeks and it was not easy to say good bye to my patients‼️. ✳️Being oncologist is a true privilege and it was true honor being part of journey of my patients❗️They will remain in my prayers….
1
5
46
Wanted start my day with a clarification as I am getting messages from my patients due to incomplete media reporting‼️. ✳️Dostarlimab was studied only Mismatch Repair Deficient Rectal Cancer seen only 5-10% only of pts‼️ @OncoAlert @colontown @CrcChange .
3
17
49
Immune checkpoint inhibitor therapy doesn’t only prolong survival outcomes but also improves quality of life of MMR-D/MSI-H colorectal cancer patients! @OncoAlert @MoffittNews
1
12
45
Excited and thrilled to co-chair #Pittsburgh First Annual Gastrointestinal Cancer Symposium ❗️. 👉With outstanding list of speakers and exciting topics, we will overview recent progress and provide a projection to the future of GI Oncology @OncoAlert @AnwaarSaeed3 @AmerZureikatMD
1
9
46
✳️It was first but also very memorable first in-person experience with #IGICC in Turkey with several GI Oncology giants from Europe and the US including Dr Van Cutsem, Dr Marc Peeter, Dr Philip Philip and Dr Ahmed Kaseb and several experts from the field @AnwaarSaeed3
0
7
46
✳️ Colorectal is increasingly being a disease of younger population and we need more creative clinical trials ❗️. ✳️ Here is the major discrepancy : Only ~6% patients living with CRC are enrolled in a therapeutic clinical trials and yet most of the precision medicine trials in
2
19
47
✳️So proud of my mentees who made it to all the way to SF to present their work ‼️#GI24. They will be presenting their work in CRC from young onset CRC to molecular subgroups of CRC‼️. ✳️Consider stopping by their posters‼️. @ASCO @UPMCHillmanCC @MasoodPashaSyed
2
8
46
✳️Starting to #colorectalcancerawareness with a great news ❗️. Our Editorial with @manjuggm @ARosen380, Dr Seth Felder and Dr Jessica Frakes discussing the most recent updates on management of locally advanced rectal cancer and the PROSPECT trial is accepted for a publication ‼️
2
5
44
✳️Was amazing to meet #KRASkickers team today ‼️ . ✳️We agreed on continuing to work together to deliver cutting edge science to our patients ❗️.Thank you @TerriConneran ❗️. @JanieYZhang
3
2
43
CIRCULATE-US is now active and recruiting❗️ I would like to increase awareness for this highly important study as it may impact future practice (also my duty as a study champion 😊) ‼️@oncoalert @CrcChange @fireflyann @manjuggm #medtwitter #ctDNA . Here is why 👇.
2
15
42
So excited that our paper accepted for publication by @JCOOP_ASCO @ASCO . ✳️Stay tuned for this highly exciting article that we discussed HER2 targeting approaches for patients with CRC‼️@OncoAlert . #PrecisionMedicine #MedTwitter
2
5
42
Our ASCO Educational Book Chapter is out!l Happy to see that in the first day of #ASCO22. ✳️We have discussed challenges of immunotherapy for MSS CRC and existing opportunities to move the field forward❗️.@OncoAlert @ASCO @manjuggm @fireflyann .Here are some take home points.
3
6
45
✳️Was exciting to join #Alliance GI committee meeting in-person and discuss and stay up to date on ongoing studies in the field and also create opportunities for collaboration to move the field forward ! . Always true pleasure and honor catching up with my life long mentor
0
2
44
Tried to carve T cell and Cancer cell interaction on my pumpkin 🎃❗️Well, would not say it was so successful even with extra help of antibody cucumbers 😄
2
6
37
Entering Thanksgiving with my amazing team by rounding on the floor☺️. ✳️Happy Thanksgiving Everyone ‼️
0
0
43
#ColorectalCancerAwarenessMonth .✳️ Science have revealed many therapeutic opportunities for the management of patients with CRC❗️. ✳️ This tweetorial is meant to create awareness precision treatments for patients with advanced stage CRC ❗️@OncoAlert @CrcChange @TheColonClub.
3
18
37
#ColorectalCancerAwarenessMonth . When determining therapeutic options for advanced stage CRC, one of the most important step is to define oligometastatic disease particularly for patients with young onset disease❗️@OncoAlert @CrcChange @DenboJw . Here is why 👇.
3
14
40
✳️The AZUR-1 trial, testing the efficacy of dostarlimab for patients with MMR-D/MSI-H rectal cancer, is now open and enrolling at @UPMCHillmanCC ‼️. ✳️This trial will serve to patients in with #lynch syndrome and rectal cancer or those with sporadic MMR-D Rectal Cancer‼️ Please.
1
12
39
Heading to Chicago for my first in person @ALLIANCE_org Spring GI Committee Meeting ‼️Very excited to see my colleagues in person after a while❗️
1
1
39
✳️ Our research article on molecular underpinnings of young onset CRC is now accepted for a publication ‼️. ✳️More to come on this interesting article ‼️. @CrcChange @manjuggm @CrcTrialsChat @DenizCanGuven1
3
2
39
✳️Just had chance to read the full article on “HER2 amplified” CRC recently published evaluating that among pts enrolled CALBG/SWOG 80405 which was contracting what is know in the field❗️. ✳️ Well, the devils is in the detail ❗️.✳️In analysis almost half of the patients were
6
14
38
#GI22 @ASCO @OncoAlert . ✳️ A Highly promising KRAS 12C inhibitor is on its way‼️#Adagrasib.✳️Even though early result, 50% of PR is quite impressive ❗️. Congrats Dr @GIcancerDoc ❗️. 👉We need more RAS inhibitors for other RAS mutations for GI cancers…
0
7
39
✳️ KRAS G12C is now among actionable alterations ❗️ In this #ASCODailyNews article Dr. @NiuSanford @jonathanloree and I discussed what makes G12C so unique for drug development compared to others ❗️.@OncoAlert @ASCO .Here is that exciting article : .
3
12
37
✳️Was amazing to see with my twitter friends @ARosen380 @CancerInsider in person ☺️, such a privilege ❗️.✳️Was so happy to hear my twitter contents contribute to awareness on colorectal cancer ❗️.✳️Look forward to working closely and help our community ❗️
1
0
36
It was delightful to finish the long day by listening the pearls of targeting DDR pathway from my life long mentor Dr. @EileenMOReilly and Dr. Bekaii-Saab @GIcancerDoc !
0
4
39
Immune checkpoint inhibitors have led to paradigm shift in MMR-D CRC management. In our multinational study we investigated predictor of IO therapy response : @MoffittNews @OncJournal @OncoAlert
2
13
37
Exciting studies in CRC #GI22 @ASCO .👉CtDNA 📈 remains single most powerful prognostic factor for recurrence . #CIRCULATE Japan .👉patients who clear ctDNA after chemo do well while persistent ctDNA predicts poor outcomes❗️.👉 Conversion ➖ to ➕ also associated with worse DFS.
🚨 The #GI22 abstracts are now available! Read the latest practice-changing findings in GI cancer treatment, research, and care ➡️ #gicsm #gionc
1
14
34